Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Noradrenaline tartrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for 2. What you need to know before you are given Noradrenaline Solution for infusion
How to take it
Noradrenaline Solution for infusion 4. Possible side effects 5. How to store Noradrenaline Solution for infusion 6. Contents of the pack and other information
1. What Noradrenaline Solution for infusion is and what it is used for
This medicine contains the active substance noradrenaline and acts as a vasoconstrictor. This medicine is only indicated for adults. This medicine is used in adults weighing over 50 kg for the treatment of hypotensive emergencies that require an immediate increase in blood pressure to a normal level.
2. What you need to know before you are given Noradrenaline Solution for infusion You must not be given Noradrenaline Solution for infusion:
- a dministered via peripheral cannula and/or peripheral vein,
- if you are allergic to noradrenaline or any of the other ingredients of this medicine (listed in section 6),
- if you are taking some anaesthetics such as halothane or cyclopropane (this may increase the risk of irregular heart beat).
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you are given Noradrenaline Solution for infusion if you:
- have major left ventricular dysfunction (a heart condition),
- have coronary (blood clot inside a blood vessel of the heart), mesenteric (blood clot in a vein that drains blood from the intestine), or peripheral vascular thrombosis (blood clot in the vein of arm or leg),
- have hypotension (low blood pressure) following myocardial infarction (heart attack),
- have Prinzmetal's variant angina,
- have heart rhythm disorders during your treatment,
- have hyperthyroidism (thyroid gland problem),
- have diabetes mellitus. Additional monitoring tests that you may be required to undergo during treatment: Your blood pressure and heart rate will be checked frequently during your treatment to avoid hypertension (high blood pressure). In cases where it is necessary to administer Noradrenaline at the same time as blood or plasma transfusion, the latter will be administered in a separate drip.
Children and adolescents
The safety and efficacy of norepinephrine in children less than 18 years of age has not been established. Therefore, use in children is not recommended.
Other medicines and Noradrenaline Solution for infusion
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. The following medicines may influence the effect of Noradrenaline Solution for infusion:
- Halothane, cyclopropane, chloroform, enflurane or other halogenated anaesthetics are contraindicated (see section 2 of this leaflet, subsection "you must not be given"): these medicines are anaesthetics, they cause insensibility to pain and are used before some operations. If you are taking these medicines as well as noradrenaline (norepinephrine) this may increase the risk of irregular heart beat.
- Amitriptiline, imipramine, trimipramine, moclobemide, iproniazide, phenelzine, fluoxetine, sertraline, desipramine: these medicines are used for treatment of depression. Taking any of these medicines together with noradrenaline (norepinephrine) can dangerously increase its concentration in the blood and therefore its pressor action.
- Digitalis glycosides may occasionally cause irregular heart beat.
- Levodopa may enhance the effects of noradrenaline (norepinephrine).
- Non-selective MAO inhibitors (or within 14days of cessation of such therapy): increase in the pressor action of the sympathomimetic which is usually moderate. Should only be used under close medical supervision.
- Selective MAO-A inhibitors: by extrapolation from non-selective MAO inhibitors, risk of increase in the pressor action. Should only be used under close medical supervision.
- Linezolid (an antibiotic), (medicine used to treat infections caused by bacteria and other microorganisms), can dangerously increase noradrenaline (norepinephrine) concentration in the blood and therefore its pressor action, when taken together.
- Methylene Blue (methemoglobinemia antidote).
- Alpha 1 agonists (e.g. midodrine): if you are taking these medicines as well as noradrenaline (norepinephrine) this may increase the risk of pronounced hypertension (high blood pressure).
- Alpha 1 blockers (e.g. prazosine, terazosine or doxazosine): if you are taking these medicines as well as noradrenaline (norepinephrine) this may reduce the pressure action of norepinephrine.
- Beta-blockers: if you are taking these medicines as well as noradrenaline (norepinephrine) this may increase the risk of severe hypertension (high blood pressure).
- Thyroid hormones: if you are taking these medicines as well as noradrenaline (norepinephrine) this may cause increased cardiac (heart) effects.
- Ergot alkaloids specifically those with relevant alpha1-agonistic action (e.g. ergotamine, dihydroergotamine, methylergometrine): may enhance the vasopressor and vasoconstrictive (increasing blood pressure) effects.
The following information is intended for medical or healthcare professionals only This is an extract from the Summary of Product Characteristics to assist in the administration of Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion. When determining appropriateness of use in a particular patient, the prescriber should be familiar with the Summary of Product Characteristics of the product.
Therapeutic indications
This medicine is indicated in adults weighing over 50kg for the treatment of hypotensive emergencies.
Posology and method of administration
Noradrenaline should only be administered as an intravenous infusion via a central venous catheter. It should be infused at a controlled rate using an infusion pump or a syringe pump, without dilution: it is supplied ready to use. Blood pressure should be monitored carefully for the duration of therapy. 108606
Posology Initial dose: The initial dose of noradrenaline base is usually between 0.05-0.15 micrograms/kg/min. Maintenance dose range: The recommended maintenance range of noradrenaline base is between 0.051.5 micrograms/kg/min. Titration of dose: Once an infusion of noradrenaline has been established the dose should be titrated in steps of 0.05 -0.1 micrograms/kg/min of noradrenaline base according to the pressor effect observed. The aim should be to establish a low normal systolic blood pressure (100 – 120 mm Hg) or to achieve an adequate mean arterial blood pressure (greater than 65 mm Hg – depending on the patient's condition).
- Lithium decreases the effect of noradrenaline (norepinephrine).
- Reserpine, amphetamine: may enhance the effects of noradrenaline (norepinephrine).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, ask your doctor or nurse for advice before using this medicine. If you are pregnant, your doctor will decide if you should be given this medicine, as noradrenaline may harm the unborn baby. No information is available on the use of noradrenaline during lactation.
Noradrenaline Solution for infusion contains sodium
This medicine contains 177.3 mg sodium (main component of cooking/table salt) in each 50 ml vial. This is equivalent to 8.9 % of the recommended maximum daily dietary intake of sodium for an adult.
3. How you are given Noradrenaline Solution for infusion Dosage
This medicine will be given to you in a hospital, by a doctor or nurse. This medicine will be administered by intravenous infusion (into a vein). The dose of this medicine will depend on your condition. Your doctor will know the best dose to use.
If you are given more Noradrenaline Solution for infusion than you should
It is unlikely that you will receive too much as this medicine will be given to you in hospital. However, talk to your doctor or nurse if you have any concerns. Symptoms that may occur if you are given too much noradrenaline are severe high blood pressure, slow heartbeat, violent headache, light sensitivity, pain in the chest, bleeding in the brain, pallor, fever, intense sweating and vomiting, fluid in the lungs causing breathlessness. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. The frequency of the listed side effects is not known (frequency cannot be estimated from the available data). Tell your doctor or nurse immediately if you experience:
- difficulty or irregularity in breathing,
- fast, slow, or irregular heart rate, palpitations,
- pain in the chest or throat. Tell your doctor or nurse as soon as possible if you experience:
- anxiety,
- headaches, tremor,
- vomiting,
- high blood pressure,
- pallor (loss of skin colour), sweating, sensitivity to light,
- gangrene (painful and cold extremities that may become purple to very dark/ black, with tissue death),
- skin necrosis if the infusion is not given directly into the vein,
- acute glaucoma (eye issue),
- retention of urine.
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Possible side effects
not listed in this leaflet. You can also report side effects directly via the national reporting system:
Duration of Treatment: The treatment should be continued until high-dose vasoactive drug support is no longer indicated, at which point, the infusion should be gradually decreased, then switched to an infusion of lower concentration. Abrupt withdrawal can result in acute hypotension.
Overdose
Symptoms Overdosage may result in headache, severe hypertension, reflex bradycardia, and decreased cardiac output. These may be accompanied by violent headache, photophobia, retrosternal pain, pallor, fever, intense sweating, pulmonary oedema and vomiting. The following may also be observed: cutaneous vasoconstriction, bed sores. Treatment In case of accidental overdose, as evidenced by excessive blood pressure elevation, discontinue the drug until the condition of the patient stabilizes.
Instructions for use and handling and disposal
This medicine should not be used if the solution is darker than slightly yellow or pink in colour or if it contains a precipitate. This medicine should not be used if it is not clear and contains particles, or if the tamper evident sealed vial is not intact. This medicinal product must not be mixed with other medicinal products. For single use only. This medicine is already diluted and ready to use. It should be used without prior dilution. It should be used with a suitable infusion pump or syringe pump capable of accurately and consistently delivering the minimum specified volume at a strictly controlled rate of infusion in line with the dose titration instructions. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
How to store it
Noradrenaline Solution for infusion
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label of the vial and the carton after EXP.The expiry date refers to the last day of that month. After the first opening, the product should be used immediately. Do not store above 25° C. Keep the vial in the outer carton in order to protect from light. Do not use this medicine if the solution is darker than slightly yellow or pink in colour or if it contains a precipitate. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Contents of the pack and other information
What Noradrenaline Solution for infusion contains:
- The active substance is noradrenaline (norepinephrine). Each mL of solution contains 0.16 mg noradrenaline (norepinephrine) tartrate equivalent to 0.08 mg noradrenaline (norepinephrine) base. Each 50 mL vial contains 8 mg noradrenaline (norepinephrine) tartrate, equivalent to 4 mg noradrenaline (norepinephrine) base.
- The other ingredients are: sodium chloride, disodium edetate, hydrochloric acid or sodium hydroxide (pH adjustment) and water for injections.
What Noradrenaline Solution for infusion looks like and contents of the pack: Clear colourless or slightly yellow solution for infusion packaged in a clear glass vial of 50 mL. Pack sizes of 1, 10 and 25 vials. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer Laboratoire AGUETTANT 1 rue Alexander Fleming 69007 LYON France
Distributed by:
AGUETTANT LTD N°1, Farleigh House – Flax Bourton BRISTOL – BS48 1UR United Kingdom
This leaflet was last revised in 01/2026 Detailed information on this medicinal product is available on the web site of Medicines and Healthcare Products Regulatory Agency (MHRA).
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. This includes any
Frequently asked questions about Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion
How do I take Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion?
Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion comes as infusion containing 0.08mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion?
The active substance in Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion is noradrenaline tartrate.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: noradrenaline tartrate
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Noradrenaline (Norepinephrine) is indicated in adults weighing over 50kg for the treatment of hypotensive emergencies.
4.2. Posology and method of administration
For intravenous use only.
Noradrenaline (Norepinephrine) should only be administered as an intravenous infusion via a central venous catheter to minimize the risk of extravasation and subsequent tissue necrosis. Noradrenaline (Norepinephrine) should be infused at a controlled rate using an infusion pump or a syringe pump.
Noradrenaline (Norepinephrine) should not be diluted before use: it is supplied ready to use. It should not be mixed with other medicines.
Blood pressure control:
Blood pressure should be monitored carefully for the duration of therapy, and preferably controlled by arterial blood pressure monitoring. The patient should be monitored carefully for the duration of noradrenaline (norepinephrine) therapy.
Posology
Initial dose:
The initial dose of noradrenaline base is usually between 0.05-0.15 micrograms/kg/min.
Maintenance dose range:
The recommended maintenance range of noradrenaline base is between 0.05-1.5 micrograms/kg/min.
Titration of dose:
Noradrenaline (Norepinephrine) should be used with a suitable infusion pump or syringe pump capable of accurately and consistently delivering the minimum specified volume at a strictly controlled rate of infusion in line with the dose titration instructions.
Once an infusion of noradrenaline has been established the dose should be titrated in steps of 0.05 -0.1 micrograms/kg/min of noradrenaline base according to the pressor effect observed. There is great individual variation in the dose required to attain and maintain normotension. The aim should be to establish a low normal systolic blood pressure (100 - 120 mm Hg) or to achieve an adequate mean arterial blood pressure (greater than 65 mm Hg – depending on the patient's condition).
Manual bolus for priming when initiating an infusion is not recommended. Caution is required during infusion relay to avoid hemodynamic instability.
Continuous noradrenaline infusion through a double pump system and an extension set reducing dead-space volume should be encouraged.
Noradrenaline (Norepinephrine) 0.08 mg/mL, solution for infusion
Patient's Weight
(kg)
Posology (µg/kg/min)
noradrenaline base
Posology (mg/h)
noradrenaline base
Infusion rate
(mL/h)
50
0.05
0.15
1.9
0.1
0.3
3.8
0.25
0.75
9.4
0.5
1.5
18.8
1
3
37.5
1.5
4.5
56.3
60
0.05
0.18
2.3
0.1
0.36
4.5
0.25
0.9
11.3
0.5
1.8
22.5
1
3.6
45.0
1.5
5.4
67.5
70
0.05
0.21
2.6
0.1
0.42
5.3
0.25
1.05
13.1
0.5
2.1
26.3
1
4.2
52.5
1.5
6.3
78.8
80
0.05
0.24
3.0
0.1
0.48
6.0
0.25
1.2
15.0
0.5
2.4
30.0
1
4.8
60.0
1.5
7.2
90.0
90
0.05
0.27
3.4
0.1
0.54
6.8
0.25
1.35
16.9
0.5
2.7
33.8
1
5.4
67.5
1.5
8.1
101.3
100
0.05
0.3
3.8
0.1
0.6
7.5
0.25
1.5
18.8
0.5
3
37.5
1
6
75.0
1.5
9
112.5
h: hour
Duration of Treatment:
The treatment should be continued until high-dose vasoactive drug support is no longer indicated, at which point, the infusion should be gradually decreased, then switched to an infusion of lower concentration. Abrupt withdrawal can result in acute hypotension.
Elderly patients
See section 4.4 Special warnings and precautions for use.
Paediatric population
Noradrenaline (Norepinephrine) is indicated for adults only.
The efficacy and safety of Noradrenaline (Norepinephrine) in 50 ml ready to use solution for infusion in children and adolescents has not been established.
Patients with renal- and hepatic impairment.
There is no experience of treatment in patients with renal- and hepatic impairment.
4.3. Contraindications
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Do not use with cyclopropane and halothane anaesthetics as this may cause serious cardiac arrhythmias including ventricular fibrillation. For interactions see section 4.5.
- Administration via peripheral cannula and/or peripheral vein.
4.4. Special warnings and precautions for use
Warning:
Noradrenaline is contraindicated in hypotensive patients in whom circulatory collapse is associated with hypovolaemia except as an emergency measure to maintain supply to the coronary and cerebral arteries until blood volume replacement therapy can be instituted.
Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate water and electrolyte replacement therapy. If plasma volumes are not corrected, hypotension may recur when the noradrenaline infusion is discontinued, or blood pressure may be maintained with the risk of severe peripheral and visceral vasoconstriction (e.g. decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischemic injury. Gangrene of extremities has been rarely reported.
Noradrenaline (Norepinephrine) is intended for infusion via a central venous catheter only.
The patients receiving noradrenaline should be closely monitored in order to identify early symptoms of vasopressor-induced limb ischaemia and implement the appropriate measures (e.g. elevation of the extremity, splinting, warming of affected limb with ad hoc device, use of vasodilating agents) to prevent progression and minimize the risks associated with necrosis of the extremities.
♦ Extravasation risk:
The infusion site should be checked frequently for free flow. Care should be taken to avoid extravasation that would cause a necrosis of the tissues surrounding the vein used for the injection. Because of the vasoconstriction of the vein wall with increased permeability, there might be some leakage of noradrenaline in the tissues surrounding the infused vein causing a blanching of the tissues which is not due to an obvious extravasation. Hence if blanching occurs, consideration should be given to changing the infusion site to allow the effects of local vasoconstriction to subside.
♦ Treatment of the ischemia due to extravasation:
During an extravascular leak of the product or an injection beside the vein, tissue destruction can appear resulting from the vasoconstrictive action of the drug on the blood vessels. The area should be infiltrated as quickly as possible with 10 to 15ml of a physiological salt solution containing 5 to 10 mg of phentolamine mesilate, an adrenergic blocking agent. For this purpose, it is necessary to use a syringe provided with a fine needle and to inject locally throughout the area, which is easily identified by its cold, hard and pallid appearance. Sympathetic blockade with phentolamine causes immediate conspicuous local hyperaemic changes if the area is infiltrated within 12 hours. Phentolamine should be given as soon as possible after the extravasation is noted and infusion should be stopped.
Precautions for use:
In general, cautious evaluation is recommended in the following cases of hypotension and hypoperfusion, in which a reduction in the dose of noradrenaline may be required:
- Major left ventricular dysfunction associated with acute hypotension. . Supportive therapy should be initiated simultaneously with diagnostic evaluation. Noradrenaline should be reserved for patients with cardiogenic shock and refractory hypotension, in particular those without elevated systemic vascular resistance.
- -Hypotensive patients diagnosed with coronary, mesenteric or peripheral vascular thrombosis, myocardial infarction or Prinzmetal's variant angina. Particular caution should be observed as noradrenaline may increase the associated ischaemia and extend the area of infarction.
- Occurrence of heart rhythm disorders during noradrenaline therapy.
- Caution is advised in patients with hyperthyroidism or diabetes mellitus.
In cases where it is necessary to administer noradrenaline at the same time as total blood or plasma, the latter must be administered in a separate drip.
This medicinal product contains sodium.
This medicinal product contains 177.3 mg sodium per vial, equivalent to 8.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
4.5. Interaction with other medicinal products and other forms of interaction
Contraindicated combinations
- Volatile halogen anaesthetics
Severe ventricular arrhythmia (increase in cardiac excitability).
Inadvisable combinations
- Tricyclic antidepressants (particularly imipramine type)
Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of sympathomimetics into sympathetic fibres).
- Serotoninergic-adrenergic antidepressants
Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of sympathomimetics into sympathetic fibres).
- Digitalis glycosides
May occasionally cause arrhythmia.
- Levodopa
May enhance the effects of noradrenaline.
Combinations requiring precautions for use
- Non-selective MAO inhibitors (or within 14 days of cessation of such therapy)
Increase in the pressor action of the sympathomimetic which is usually moderate. Should only be used under close medical supervision.
- Selective MAO-A inhibitors, Linezolid and Methylene Blue
By extrapolation from non-selective MAO inhibitors, risk of increase in the pressor action. Should only be used under close medical supervision.
- Alpha 1 agonists (e.g. midodrine)
Caution is required as pronounced hypertension may result.
- Alpha 1 blockers (e.g. prazosine, terazosine or doxazosine)
May reduce the pressure action of norepinephrine.
- Beta blockers
Caution is required as severe hypertension may result.
- Thyroid hormones,
Caution is required as they may cause increased cardiac effects.
- Ergot alkaloids, specifically those with relevant alpha1-agonistic action (e.g. ergotamine, dihydroergotamine, methylergometrine)
May enhance the vasopressor and vasoconstrictive effects.
- Lithium
Decreases the effect of noradrenaline
- Reserpine, amphetamine
May enhance the effects of noradrenaline.
4.6. Fertility, pregnancy and lactation
Pregnancy
Because of its indications, noradrenaline may be administered if necessary during pregnancy.
However, pharmacodynamics properties of the substance have to be considered. Indeed noradrenaline may impair placental perfusion and induce fetal bradycardia. It may also exert a contractile effect on the pregnant uterus and lead to fetal asphyxia in late pregnancy.
Breast-feeding
No information is available on the use of noradrenaline in breast-feeding.
4.7. Effects on ability to drive and use machines
Noradrenaline has no influence on the ability to drive and use machines.
4.8. Undesirable effects
Very common: ≥1/10 ; Common : ≥1/100, <1/10 ; Uncommon: ≥1/1,000, <1/100 ; Rare: ≥1/10,000, <1/1,000; Very rare: <1/10,000; Not known: cannot be estimated from the available data.
System Organ Class (SOC)
Adverse Reactions (Frequency: not known)
Psychiatric disorders
Anxiety,.
Nervous system disorders
Headaches, tremor,
Eyes disorders
Acute glaucoma (very frequent in patients anatomically predisposed with the closing of the iridocorneal angle).
Cardiac disorders
Tachycardia, bradycardia (probably as a reflex result of blood pressure rising), arrhythmias, palpitations, increase in the contractility of the cardiac muscle resulting from the ß adrenergic effect on the heart (inotrope and chronotrope), acute cardiac insufficiency, stress cardiomyopathy.
Vascular disorders
Arterial hypertension and tissue hypoxia; ischemic injury due to potent vasoconstrictor action (may result in coldness and paleness of the skin, members (peripheries) and the face), gangrene of the extremities, cyanosis.
Respiratory, thoracic and mediastinal disorders
Respiratory insufficiency or difficulty, dyspnoea.
Gastrointestinal disorders
Vomiting
Renal and urinary disorders
Retention of urine.
General disorders and administration site conditions
Possibility of irritation and necrosis at the injection site
In case of hypersensitivity or overdose, the following effects may appear more frequently: hypertension, photophobia, retrosternal pain, pharyngeal pain, pallor, intense sweating and vomiting.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system:
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
♦ Symptoms
Overdosage may result in headache, severe hypertension, reflex bradycardia, and decreased cardiac output.
These may be accompanied by violent headache, photophobia, retrosternal pain, pallor, fever, intense sweating, pulmonary oedema and vomiting.
The following may also be observed: cutaneous vasoconstriction, bed sores.
♦ Treatment
In case of accidental overdose, as evidenced by excessive blood pressure elevation, discontinue the drug until the condition of the patient stabilizes.
🇷🇴 Known in Romania as
Medicines sold in Romania with the same active substance: Cunoscut în România ca
- NORADRENALINA AMDIPHARM 1 mg/ml prescriptionNORADRENALINUM · injection / infusion
- NORADRENALINA KALCEKS 1 mg/ml prescriptionNORADRENALINUM · injection / infusion
- NORADRENALINA KABI 1 mg/ml prescriptionNORADRENALINUM · injection / infusion
- NORADRENALINA TARTRAT HYPERICUM 2 mg/ml prescriptionNORADRENALINUM · injection / infusion
- MYKRONOR 10 micrograme/ml prescriptionNORADRENALINUM · injection / infusion
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
🇵🇱 Known in Poland as
Medicines sold in Poland with the same active substance: W Polsce znany jako
- LevonorNoradrenalinum · injection / infusion
- SinoraNoradrenalinum · injection / infusion
- Norepinephrine SopharmaNoradrenalinum · injection / infusion
- Noradrenaline AguettantNoradrenalini tartras · injection / infusion
- Noradrenalin KalceksNoradrenalinum · injection / infusion
- Noradrenaline hamelnNoradrenalinum · injection / infusion
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
💬 Ask about this leaflet
Ask anything about Noradrenaline (Norepinephrine) 0.08 mg/ml, solution for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.